Brokerages expect that AC Immune SA (NASDAQ:ACIU) will announce sales of $106.81 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AC Immune’s earnings. The lowest sales estimate is $81.28 million and the highest is $132.34 million. AC Immune posted sales of $1.58 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 6,660.1%. The business is scheduled to report its next earnings results on Wednesday, May 15th.
According to Zacks, analysts expect that AC Immune will report full-year sales of $120.51 million for the current financial year, with estimates ranging from $60.98 million to $162.67 million. For the next financial year, analysts anticipate that the company will post sales of $62.40 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover AC Immune.
AC Immune (NASDAQ:ACIU) last released its earnings results on Thursday, March 21st. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.55 by ($0.77). The company had revenue of $1.41 million during the quarter, compared to the consensus estimate of $56.97 million. AC Immune had a negative return on equity of 33.97% and a negative net margin of 706.11%.
Shares of ACIU traded up $0.04 during midday trading on Friday, hitting $5.11. The company had a trading volume of 8,044 shares, compared to its average volume of 128,732. The company has a market capitalization of $346.60 million, a P/E ratio of -6.27 and a beta of 0.01. AC Immune has a 52 week low of $3.25 and a 52 week high of $17.40.
Institutional investors and hedge funds have recently bought and sold shares of the business. Alps Advisors Inc. acquired a new stake in AC Immune in the 4th quarter valued at about $1,471,000. JPMorgan Chase & Co. acquired a new stake in AC Immune in the 3rd quarter valued at about $142,000. BlackRock Inc. bought a new position in shares of AC Immune in the 4th quarter valued at about $6,092,000. FMR LLC boosted its stake in shares of AC Immune by 7.7% in the 4th quarter. FMR LLC now owns 5,612,759 shares of the company’s stock valued at $53,039,000 after purchasing an additional 403,086 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of AC Immune in the 1st quarter valued at about $397,000. Hedge funds and other institutional investors own 27.80% of the company’s stock.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.